Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea

Middle East Fertility Society Journal

Volumn 13, Issue 1, 2008, Pages 33-38

  Al Husaynei, Ahmed J ^a   Mahmood, Isam H ^a,b   Al Jubori, Zena S ^a  

^a UNIVERSITY OF MOSUL   (Iraq)

^b UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

Amenorrhea; Bromocriptine; Cabergoline; Galactorrhea; Hyperprolactinemia

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; PROLACTIN;

ABDOMINAL PAIN; ADULT; AMENORRHEA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DIZZINESS; DROWSINESS; DRUG EFFICACY; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NAUSEA; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; TREATMENT OUTCOME; VOMITING;

EID: 47749121809     PISSN: 11105690     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treatments in Endocrinology 2003; 2: 23-32.
2. Mah PM, Webster L. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002; 20: 365-374.
3. Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 1999; 44: 1085-1090.
4. De Luis DA, Becerra A, Lahera M, Botella JI, Valero MA, Varela C. A randomized coss-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest 2000; 23: 428-434
5. Barlier A, Jaquet P. Quinagolide a valuable treatment option for hyperprolactinaemia. European J Endocrinol 2006; 154: 187-195.
6. Biller BM. Hyperprolactinemia. Int J Fertil Women's Med 1999; 44: 74-77.
7. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003; 46: 349-362.
8. Webster J. Dopamine agonist therapy in hyperprolactinemia. J Reprod Med 1999; 44(12 suppl): 1105-1110.
9. Lamberts SW, Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991; 72: 635-641.
10. Kletzky OA, Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertility and Sterility 1989; 51: 269-272.
11. Ginsburg J, Hardiman P, Thomas M. Vaginal bromocriptine - clinical and biochemical effects. Gynecological Endocrinology 1992; 6: 119-126.
12. Brue T, Pellegrinil I, Priou A, Morang I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Hormone Research 1992; 38: 84-89.
13. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876-883.
14. Verhelst J, Abs R, Maiter D, van der Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol and Metab 1999; 84: 2518-2522.
15. Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacok 2003; 42: 633-645.
16. Leung AKC, Pacand D. Diagnosis and management of galactorrhea. American Family Physician 2004; 70: 543-550.
17. Serri O, Chik CL, Ehud Ur, Ezzat S. Diagnosis and management of hyperprolactinemia. Canad Med Ass J 2003; 169: 575-581.
18. Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus 16 (4), 2004. American Association of Neurological Surgeon. Available at internet website related to Medscape. http://www.Medscape.Com/viewarticle/ 474899.
19. Huskisson E, Wojtulewski JA. Measurement of side effects of drugs. Br Med J 1974; 2: 698-699.
20. Buvat J, buvat-Herbaut M. Prolactin, bromocriptine and gonadal function in women: recent advances.11. Treatment of female hyperprolactinemia and other indications for the use of bromocriptine. J Gynecol Obstet Biol Reprod (Paris) 1982; 11: 509-521.
21. Al-Suleiman SA, Najashi S, Rahman J MS. Outcome of treatment with bromocriptine in patients with hyperprolactinaemia. Aust NZJ Obstet Gynaecol 1989; 176-179.
22. Tartagni M, Nicastri PL, Diaferia A, Di Gesu l, Loizzi P. Long term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine. Clin Exp Obstet Gynecol 1995; 22: 301-306.
23. Van der Heijden PF, de Wit W, Brownell J, Schoemaker J, Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. European J Obstet Gynecol Reprod Biology 1991; 40: 111-118.
24. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemia amenorrhea. New England J Med 1994; 331: 904-909.
25. Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 2001; 40: 857-861.
26. Pascal- Vigneron V, Weryha G, Bosc M, Lectere J. Hyperprolactinemic amenorrhea: treatment with cabergoline vs bromocriptine. Results of a national multicenter randomized double blind study. Press Med 1995; 24: 753-757.
27. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D' Alberton A, Crosignani P. Cabergoline in the long term therapy of hyprerprolactinemic disorders,. Arch Endocrinol (Copenh) 1992; 126: 489-494.
28. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-2343.
29. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrin Metab 2000; 85: 2247-2252.
30. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation. Drugs 1995; 49: 255-279.